|Day Low/High||47.56 / 50.73|
|52 Wk Low/High||7.42 / 55.38|
A lot of these stocks have been beneficiaries of the additional focus on the need for testing.
A close above $18 would go a long way towards making breakout buyers feel better.
These ARK Funds family funds are focused on new opportunities and investment themes.
The market has weakened just a tad since our last update but remains directionless. The Energy sector continues to be the weakest of the 11 S&P sectors this year and the Energy Select Sector SPDR is off another 1% today and that is with oil prices b...
What is most notable about this market action is that it never seems to fully discount the optimism about a China trade deal.
They're the most important executive at most small developmental or early commercialization concerns.
If the macro issues calm down there should be some good trade opportunities.
The market action is creating some mis-pricing in individual stocks. But if the market stays under pressure then stock picking will remain difficult.
Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.
I don't expect to see the bears and shorts press too hard right now but there isn't going to be much upside momentum.
Ark Invest has developed a series of specialized exchange-traded funds that own shares in companies involved in 'disruptive innovation.'
When the indices aren't offering much opportunity money flows into individual speculative names.
One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
Diagnostic firms can have an advantage of recurring revenue streams.
Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.
BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.
Your questions are answered in our latest addition of the biotech mailbag.
Some good discussions today on the Daily Diary. Look forward to continuing the conversation tomorrow as we look to wrap up a solid week for equities. Market was lackluster today but had a ton of earnings reports to take into account. Not to mention ...
V-shaped moves are more common than they used to be.
Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.
The rapidly growing genetic testing concern is executing its growth plan marvelously.
Garvis Toler, head of global capital markets at the NYSE, reviews the landscape of IPOs during the first half of 2015 and previews what's in store for the second half.